Global Hormone Refractory Breast Cancer Market Research Report 2023

Report ID: 1875830 | Published Date: Oct 2024 | No. of Page: 82 | Base Year: 2023 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Tumor Markers Therapy
        1.2.3 Gene Expression Therapy
        1.2.4 Gene Mutation Therapy
    1.3 Market by Application
        1.3.1 Global Hormone Refractory Breast Cancer Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Scientific Research and Production
        1.3.3 Biological Science and Technology
        1.3.4 Medical Technology
        1.3.5 Medical Apparatus and Instruments
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Hormone Refractory Breast Cancer Market Perspective (2017-2028)
    2.2 Hormone Refractory Breast Cancer Growth Trends by Region
        2.2.1 Hormone Refractory Breast Cancer Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Hormone Refractory Breast Cancer Historic Market Size by Region (2017-2022)
        2.2.3 Hormone Refractory Breast Cancer Forecasted Market Size by Region (2023-2028)
    2.3 Hormone Refractory Breast Cancer Market Dynamics
        2.3.1 Hormone Refractory Breast Cancer Industry Trends
        2.3.2 Hormone Refractory Breast Cancer Market Drivers
        2.3.3 Hormone Refractory Breast Cancer Market Challenges
        2.3.4 Hormone Refractory Breast Cancer Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Hormone Refractory Breast Cancer Players by Revenue
        3.1.1 Global Top Hormone Refractory Breast Cancer Players by Revenue (2017-2022)
        3.1.2 Global Hormone Refractory Breast Cancer Revenue Market Share by Players (2017-2022)
    3.2 Global Hormone Refractory Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Hormone Refractory Breast Cancer Revenue
    3.4 Global Hormone Refractory Breast Cancer Market Concentration Ratio
        3.4.1 Global Hormone Refractory Breast Cancer Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Breast Cancer Revenue in 2021
    3.5 Hormone Refractory Breast Cancer Key Players Head office and Area Served
    3.6 Key Players Hormone Refractory Breast Cancer Product Solution and Service
    3.7 Date of Enter into Hormone Refractory Breast Cancer Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Hormone Refractory Breast Cancer Breakdown Data by Type
    4.1 Global Hormone Refractory Breast Cancer Historic Market Size by Type (2017-2022)
    4.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2023-2028)
5 Hormone Refractory Breast Cancer Breakdown Data by Application
    5.1 Global Hormone Refractory Breast Cancer Historic Market Size by Application (2017-2022)
    5.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Hormone Refractory Breast Cancer Market Size (2017-2028)
    6.2 North America Hormone Refractory Breast Cancer Market Size by Country (2017-2022)
    6.3 North America Hormone Refractory Breast Cancer Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Hormone Refractory Breast Cancer Market Size (2017-2028)
    7.2 Europe Hormone Refractory Breast Cancer Market Size by Country (2017-2022)
    7.3 Europe Hormone Refractory Breast Cancer Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Hormone Refractory Breast Cancer Market Size (2017-2028)
    8.2 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Country (2017-2022)
    8.3 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Hormone Refractory Breast Cancer Market Size (2017-2028)
    9.2 Latin America Hormone Refractory Breast Cancer Market Size by Country (2017-2022)
    9.3 Latin America Hormone Refractory Breast Cancer Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Hormone Refractory Breast Cancer Market Size (2017-2028)
    10.2 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2017-2022)
    10.3 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 AstraZeneca
        11.1.1 AstraZeneca Company Detail
        11.1.2 AstraZeneca Business Overview
        11.1.3 AstraZeneca Hormone Refractory Breast Cancer Introduction
        11.1.4 AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        11.1.5 AstraZeneca Recent Development
    11.2 AmpliMed Corporation
        11.2.1 AmpliMed Corporation Company Detail
        11.2.2 AmpliMed Corporation Business Overview
        11.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Introduction
        11.2.4 AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        11.2.5 AmpliMed Corporation Recent Development
    11.3 Roche
        11.3.1 Roche Company Detail
        11.3.2 Roche Business Overview
        11.3.3 Roche Hormone Refractory Breast Cancer Introduction
        11.3.4 Roche Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        11.3.5 Roche Recent Development
    11.4 Bluefish Pharmaceuticals AB
        11.4.1 Bluefish Pharmaceuticals AB Company Detail
        11.4.2 Bluefish Pharmaceuticals AB Business Overview
        11.4.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Introduction
        11.4.4 Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        11.4.5 Bluefish Pharmaceuticals AB Recent Development
    11.5 NeoCorp
        11.5.1 NeoCorp Company Detail
        11.5.2 NeoCorp Business Overview
        11.5.3 NeoCorp Hormone Refractory Breast Cancer Introduction
        11.5.4 NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        11.5.5 NeoCorp Recent Development
    11.6 Sanofi Genzyme
        11.6.1 Sanofi Genzyme Company Detail
        11.6.2 Sanofi Genzyme Business Overview
        11.6.3 Sanofi Genzyme Hormone Refractory Breast Cancer Introduction
        11.6.4 Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        11.6.5 Sanofi Genzyme Recent Development
    11.7 Neopharm
        11.7.1 Neopharm Company Detail
        11.7.2 Neopharm Business Overview
        11.7.3 Neopharm Hormone Refractory Breast Cancer Introduction
        11.7.4 Neopharm Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        11.7.5 Neopharm Recent Development
    11.8 Boehringer Ingelheim GmbH
        11.8.1 Boehringer Ingelheim GmbH Company Detail
        11.8.2 Boehringer Ingelheim GmbH Business Overview
        11.8.3 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Introduction
        11.8.4 Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2017-2022)
        11.8.5 Boehringer Ingelheim GmbH Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Tumor Markers Therapy
    Table 3. Key Players of Gene Expression Therapy
    Table 4. Key Players of Gene Mutation Therapy
    Table 5. Global Hormone Refractory Breast Cancer Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Hormone Refractory Breast Cancer Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Hormone Refractory Breast Cancer Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Hormone Refractory Breast Cancer Market Share by Region (2017-2022)
    Table 9. Global Hormone Refractory Breast Cancer Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Hormone Refractory Breast Cancer Market Share by Region (2023-2028)
    Table 11. Hormone Refractory Breast Cancer Market Trends
    Table 12. Hormone Refractory Breast Cancer Market Drivers
    Table 13. Hormone Refractory Breast Cancer Market Challenges
    Table 14. Hormone Refractory Breast Cancer Market Restraints
    Table 15. Global Hormone Refractory Breast Cancer Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Hormone Refractory Breast Cancer Market Share by Players (2017-2022)
    Table 17. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Breast Cancer as of 2021)
    Table 18. Ranking of Global Top Hormone Refractory Breast Cancer Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Hormone Refractory Breast Cancer Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Hormone Refractory Breast Cancer Product Solution and Service
    Table 22. Date of Enter into Hormone Refractory Breast Cancer Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Hormone Refractory Breast Cancer Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2017-2022)
    Table 26. Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2023-2028)
    Table 28. Global Hormone Refractory Breast Cancer Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Hormone Refractory Breast Cancer Revenue Market Share by Application (2017-2022)
    Table 30. Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Hormone Refractory Breast Cancer Revenue Market Share by Application (2023-2028)
    Table 32. North America Hormone Refractory Breast Cancer Market Size by Country (2017-2022) & (US$ Million)
    Table 33. North America Hormone Refractory Breast Cancer Market Size by Country (2023-2028) & (US$ Million)
    Table 34. Europe Hormone Refractory Breast Cancer Market Size by Country (2017-2022) & (US$ Million)
    Table 35. Europe Hormone Refractory Breast Cancer Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region (2017-2022) & (US$ Million)
    Table 37. Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region (2023-2028) & (US$ Million)
    Table 38. Latin America Hormone Refractory Breast Cancer Market Size by Country (2017-2022) & (US$ Million)
    Table 39. Latin America Hormone Refractory Breast Cancer Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2023-2028) & (US$ Million)
    Table 42. AstraZeneca Company Detail
    Table 43. AstraZeneca Business Overview
    Table 44. AstraZeneca Hormone Refractory Breast Cancer Product
    Table 45. AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 46. AstraZeneca Recent Development
    Table 47. AmpliMed Corporation Company Detail
    Table 48. AmpliMed Corporation Business Overview
    Table 49. AmpliMed Corporation Hormone Refractory Breast Cancer Product
    Table 50. AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 51. AmpliMed Corporation Recent Development
    Table 52. Roche Company Detail
    Table 53. Roche Business Overview
    Table 54. Roche Hormone Refractory Breast Cancer Product
    Table 55. Roche Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 56. Roche Recent Development
    Table 57. Bluefish Pharmaceuticals AB Company Detail
    Table 58. Bluefish Pharmaceuticals AB Business Overview
    Table 59. Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Product
    Table 60. Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 61. Bluefish Pharmaceuticals AB Recent Development
    Table 62. NeoCorp Company Detail
    Table 63. NeoCorp Business Overview
    Table 64. NeoCorp Hormone Refractory Breast Cancer Product
    Table 65. NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 66. NeoCorp Recent Development
    Table 67. Sanofi Genzyme Company Detail
    Table 68. Sanofi Genzyme Business Overview
    Table 69. Sanofi Genzyme Hormone Refractory Breast Cancer Product
    Table 70. Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 71. Sanofi Genzyme Recent Development
    Table 72. Neopharm Company Detail
    Table 73. Neopharm Business Overview
    Table 74. Neopharm Hormone Refractory Breast Cancer Product
    Table 75. Neopharm Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 76. Neopharm Recent Development
    Table 77. Boehringer Ingelheim GmbH Company Detail
    Table 78. Boehringer Ingelheim GmbH Business Overview
    Table 79. Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Product
    Table 80. Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2017-2022) & (US$ Million)
    Table 81. Boehringer Ingelheim GmbH Recent Development
    Table 82. Research Programs/Design for This Report
    Table 83. Key Data Information from Secondary Sources
    Table 84. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Hormone Refractory Breast Cancer Market Share by Type: 2021 VS 2028
    Figure 2. Tumor Markers Therapy Features
    Figure 3. Gene Expression Therapy Features
    Figure 4. Gene Mutation Therapy Features
    Figure 5. Global Hormone Refractory Breast Cancer Market Share by Application in 2021 & 2028
    Figure 6. Scientific Research and Production Case Studies
    Figure 7. Biological Science and Technology Case Studies
    Figure 8. Medical Technology Case Studies
    Figure 9. Medical Apparatus and Instruments Case Studies
    Figure 10. Hormone Refractory Breast Cancer Report Years Considered
    Figure 11. Global Hormone Refractory Breast Cancer Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 12. Global Hormone Refractory Breast Cancer Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Hormone Refractory Breast Cancer Market Share by Region: 2021 VS 2028
    Figure 14. Global Hormone Refractory Breast Cancer Market Share by Players in 2021
    Figure 15. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Breast Cancer as of 2021)
    Figure 16. The Top 10 and 5 Players Market Share by Hormone Refractory Breast Cancer Revenue in 2021
    Figure 17. North America Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 18. North America Hormone Refractory Breast Cancer Market Share by Country (2017-2028)
    Figure 19. United States Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Canada Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Hormone Refractory Breast Cancer Market Share by Country (2017-2028)
    Figure 23. Germany Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. France Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. U.K. Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Italy Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Russia Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Nordic Countries Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Asia-Pacific Hormone Refractory Breast Cancer Market Share by Region (2017-2028)
    Figure 31. China Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Japan Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. South Korea Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Southeast Asia Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. India Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Australia Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Latin America Hormone Refractory Breast Cancer Market Share by Country (2017-2028)
    Figure 39. Mexico Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Brazil Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Middle East & Africa Hormone Refractory Breast Cancer Market Share by Country (2017-2028)
    Figure 43. Turkey Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Saudi Arabia Hormone Refractory Breast Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. AstraZeneca Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 46. AmpliMed Corporation Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 47. Roche Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 48. Bluefish Pharmaceuticals AB Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 49. NeoCorp Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 50. Sanofi Genzyme Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 51. Neopharm Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 52. Boehringer Ingelheim GmbH Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2017-2022)
    Figure 53. Bottom-up and Top-down Approaches for This Report
    Figure 54. Data Triangulation
    Figure 55. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH
Frequently Asked Questions
Hormone Refractory Breast Cancer report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Hormone Refractory Breast Cancer report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Hormone Refractory Breast Cancer report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports